Background
Results
There was no difference in related genitourinary adverse events between treatment arms compared to placebo. Dapivirine and maraviroc concentrations rose higher initially before falling more rapidly with the combination ring compared to relatively stable concentrations with the single drug rings. Dapivirine concentrations in CVF were 1 and 5 log 10 greater than cervical tissue and plasma for both rings. Maraviroc was consistently detected only in CVF. Dapivirine and maraviroc CVF and dapivirine tissue concentrations dropped rapidly after ring removal.
Cervical tissue showed a significant inverse linear relationship between HIV replication and dapivirine levels.
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Conclusions
In this first study of a combination microbicide vaginal ring, all four rings were safe and well tolerated. Tissue dapivirine concentrations were 1,000 times greater than plasma concentrations and single drug rings had more stable pharmacokinetics. Dapivirine, but not maraviroc, demonstrated concentration-dependent inhibition of HIV-1 infection in cervical tissue. Since maraviroc concentrations were consistently detectable only in CVF and not in plasma, improved drug release of maraviroc rings is needed.
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INTRODUCTION
Microbicides are topically-applied products designed to prevent sexual acquisition of HIV through pre-exposure prophylaxis (PrEP). Vaginal tenofovir gel was partially protective when used before and after intercourse. However, lower adherence was associated with higher rates of HIV acquisition. 1 Several daily oral and vaginal dosing PrEP trials also found low rates of adherence, which impacts effectiveness. 2, 3 Vaginal rings providing sustained drug release hold promise for increased adherence compared to products requiring daily dosing. Additionally, rings have the capacity to release multiple antiretrovirals (ARV), which may reduce the risk of acquisition of ARV-resistant HIV. Topical administration also provides the highest ARV concentrations in genital tissues, the site of transmission in sexually-acquired HIV.
Dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is under evaluation as a microbicide in vaginal ring, gel, and film formulations. [4] [5] [6] [7] [8] [9] [10] Two randomized controlled trials are testing the efficacy of DPV vaginal rings for PrEP. 11,12 Although DPV is not effective against HIV-2, the global incidence of HIV-2 sexual transmission is vastly lower compared to that of HIV-1. 13 As a drug class, NNRTIs are attractive candidates for the prevention of sexually transmitted HIV-1 due to high concentrations in the female genital mucosa when administered systemically. 14 However, the potential for development of resistance to this class is high, especially in cases of intermittent or noncompliant use. Rings were used continuously for 28 days, followed by 24 days off product. The study was conducted at the University of Pittsburgh (Pittsburgh, PA), the University of Alabama at
A C C E P T E D
Birmingham (Birmingham, AL), and Fenway Institute (Boston, MA). All sites received institutional review board approval.
The vaginal ring was an off-white, flexible ring (56 mm outer diameter × 7.7 mm cross-sectional diameter) containing drug dispersed in a platinum-catalyzed-cured silicone matrix designed for sustained release of drug over at least 28 days. The placebo ring was manufactured with the same components, except it contained USP titanium dioxide as a colorant for blinding.
The primary objectives were to assess the safety of vaginal rings and the PK of DPV and MVC in cervicovaginal fluid (CVF), plasma and cervical tissue. Safety was evaluated as the proportion of women with related genitourinary adverse events (AEs) and proportion of women with any grade 2 or higher AEs, using the Division of AIDS For residual drug analysis, rings were cut into four pieces, combined in a bottle with 100 mL of acetone, and agitated for 24 hours at 180 rpm. An aliquot was removed, evaporated to dryness under nitrogen, reconstituted with acetonitrile, mixed, and centrifuged. An aliquot of supernatant was transferred to a 10 mL volumetric flask and diluted to volume with water. Samples were analyzed by isocratic reversed phase high performance liquid chromatography with ultraviolet detection at 210 nm.
Demographic and adherence data were analyzed using descriptive statistics. For the primary AE endpoints, each treatment arm was compared with placebo using Fisher's exact test. Descriptive statistics (median, interquartile ranges [IQR]) were used to summarize non-compartmental PK parameters, including area under the concentration-time curve to infinity (AUC inf ), time to peak concentration (T max ), peak concentration (C max ), and day 28 concentration (C 28D ) at time of ring removal. PK parameters specific to each drug were compared among anatomical sites sampled and between study arms using Wilcoxon-Mann-Whitney rank sum tests.
Fresh cervical tissue samples from Pittsburgh were used for the ex vivo challenge assay.
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Cervical biopsies were transported to the laboratory within 30 minutes and exposed to HIV-1 BaL for two hours, washed and placed in culture. Supernatant was collected and replenished on days 4, 7, 11, 14, and 17 of culture. On day 21, the biopsies were removed from culture, weighed, and placed in paraformaldehyde. HIV-1 replication was monitored in the supernatant using a p24gag
ELISA (Alliance, Perkin-Elmer, Waltham, MA). Data from participants using the DPV-only, MVC-only and DPV/MVC rings were combined for the PK/PD analysis. DPV and MVC (ng/mL) detected concentrations at Day 28 were log 10 transformed. Non-detected DPV and MVC (ng/mL) were imputed at ½ the median tissue weight LLOQ of 50 and 200 for DPV and MVC, respectively. The p24 at Days 4, 7, and 11 of the ex vivo assay were used in a linear, least squares regression, with subject as a covariate factor, to model the PK endpoints at Day 28, where a negative slope would support the finding of drug-mediated virus suppression. Ex vivo samples that were acellular on histology were excluded from analysis.
Vaginal swabs were collected from all participants at baseline and on days 7, 28, and 52, and cultured for aerobic and anaerobic bacteria. Nugent scores were assessed at baseline and on days 3, 28, 31, and 52. Modified Poisson regression and generalized estimating equations were used to assess the effect of ring use on prevalence of vaginal microflora and Gram stain Nugent score.
Quantity of biofilm was measured by a semi-quantitative assessment of scanning electron microscopy photographs at 25× magnification.
RESULTS
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The study was conducted between September 2011 and September 2012, and enrolled 48 women from Pittsburgh (n=24), Birmingham (n=16), and Boston (n=8). Participant characteristics by study arm (Table 1) and study flow (Figure 1 ) are presented. Forty-seven participants (98%) completed the study. One participant withdrew for personal reasons after day 29; data obtained prior to withdrawal were analyzed.
A total of 33 grade 1 and one grade 2 related genitourinary AEs were observed in 22 women.
There were no statistically significant differences in the number of participants with related Figure 2A) . The CVF C max was lower with the DPV ring compared to the DPV/MVC ring (Table 2 , p=0.002). CVF AUC inf also trended lower (p=0.08). In the week after ring removal, the CVF DPV concentrations fell to undetectable concentrations in all but one participant in each arm and were below detection in all participants from day 42 onward.
Day 28 tissue DPV concentrations were similar among DPV and DPV/MVC ring users (Table   2 ). Tissue DPV concentrations were quantifiable in all DPV users and 11 of 12 (92%) DPV/MVC users. Tissue DPV concentrations were roughly 4 log 10 greater than plasma and 1 log 10 lower than CVF concentrations. Tissue DPV concentrations dropped rapidly after ring removal, and were below LLOQ by day 31. In addition, MVC is a substrate of p-glycoprotein and has been shown to have much greater permeability in cell cultures in the basolateral to apical direction than in the opposite direction. Almost all women were adherent with 28 days of ring use by self-report. The high adherence is promising for further development of vaginal rings given the impact of low adherence of daily microbicides on microbicide efficacy. 3 Since adherence to ring use was primarily assessed by self-report, high adherence rates could have been affected by social desirability and response bias. However, residual drug levels in returned rings in this study were comparable to a previous study conducted by IPM that also found approximately 4 mg of dapivirine released from the rings over 28 days, 4 thus the rings were likely used as instructed. In addition, adherence was assessed by both CASI and face-to-face interview, and responses by CASI are expected to be less susceptible to social desirability bias. However, since CVF and cervical tissue DPV levels 
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Division of AIDS
24.
Division of AIDS pg/mL. The pharmacokinetic (MVC or DPV) and pharmacodynamic (p24) data were fit with an inverse, linear least squares regression at each day of the ex vivo assay with significance noted.
Data below the limit of quantification were imputed as half the lower limit of quantification (DPV = 1.6 log 10 ng/mL; MVC = 1.0 log 10 ng/mL) and indicated with a vertical dotted line in the figures.
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DPV, dapivirine; MVC, maraviroc; LLOQ, lower limit of quantification; VR, vaginal ring A C C E P T E D The lower limits of quantification for DPV in plasma and CVF were 20 pg/mL and 0.05 ng/tear strip (2 pg/mg based on typical sample weights), respectively. The lower limits of quantification for MVC in plasma and CVF were 0.5 ng/mL and 0.025 ng/tear strip (1 pg/mg), respectively. 
